Adaptive Biotechnologies Corp Dossier - Source-backed chat

Adaptive Biotechnologies Corp

ADPTNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)1.73

Intrinsic Value $11.95median of 2 methodsbased on filings through 30 Jun 2026

Market Price $28.90Price as of 30 Sep 2026

Significantly overvaluedIntrinsic value is 59% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-59%)

Data confidence Sign in to view data confidence

Market Cap $4.6B

Enterprise Value $4.4B

Shares Outstanding 158.8M diluted

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Adaptive Biotechnologies is undergoing a major structural transformation by separating its highly profitable, rapidly growing Minimal Residual Disease (MRD) diagnostics business (clonoSEQ) from its AI-driven Immune Medicine discovery platform. This strategic split, targeted for completion by year-end 2026, is poised to unlock significant shareholder value. The core MRD business is already profitable on an Adjusted EBITDA basis and is growing at a >50% clinical volume trajectory, supported by expanding blood-based testing and community oncology adoption. Meanwhile, the recent $300 million convertible notes offering successfully addresses high-cost legacy debt, extending the company's runway to achieve company-wide positive Adjusted EBITDA and free cash flow by the end of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$21.00

Mean target$25.07

High · most bullish analyst$28.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$21.00

The separation process faces regulatory, tax, or operational delays, keeping the cash-burning Immune Medicine segment consolidated under Adaptive for longer than expected. Dilution from the $300 million convertible notes pressures EPS, while clonoSEQ volume growth slows due to intense competition in the liquid biopsy space from larger players like Natera and Guardant Health. Average Selling Price (ASP) fails to reach the targeted $1,400 due to payer reimbursement friction.

Base CaseCentral scenario

$25.07

Matches the consensus mean

The MRD business continues its steady expansion, meeting the raised FY 2026 revenue guidance of $260M-$270M (22-27% growth) and achieving sequencing gross margins of ~70%. The separation of the MRD and Immune Medicine units is finalized by late 2026, allowing the market to value clonoSEQ on its strong diagnostic cash flows. The company achieves consolidated positive Adjusted EBITDA and free cash flow by late 2026, supported by the elimination of OrbiMed debt using the proceeds from the upsized $300M convertible notes.

Bull CaseUpside scenario

$28.00

The separation of the business units proceeds seamlessly, establishing clonoSEQ as a standalone, high-margin diagnostic leader with sequencing gross margins exceeding 75%. Rapid adoption of blood-based testing (surpassing 50% of mix) and deep penetration into community oncology drive MRD revenues above the high end of guidance. Concurrently, the Immune Medicine business secures multiple high-value AI data-licensing partnerships similar to the Pfizer agreement, validating its TCR-antigen library and generating substantial non-dilutive cash.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum of clonoSEQ, which delivered 41% volume growth in Q1 2026 and is backed by over 300 million covered lives.
Value-unlock potential from the planned separation of the diagnostic (MRD) and AI-driven discovery (Immune Medicine) business units.
Improved balance sheet flexibility following the $300 million convertible notes offering, which retires expensive OrbiMed debt and funds share repurchases.
Transitioning toward company-wide profitability, with MRD already segment-profitable and consolidated positive Adjusted EBITDA targeted by late 2026.

Key Investment Risks

Execution and friction risks associated with the corporate separation of the two business units by year-end 2026.
Potential equity dilution from the newly issued $300 million convertible senior notes due 2031.
Intense competition in the molecular diagnostics and minimal residual disease testing market from well-capitalized peers.
Dependence on favorable payer coverage and clinical ASP expansion to sustain high gross margins.

Thesis Invalidation Triggers

Failure to identify or execute a viable separation path for the Immune Medicine business by year-end 2026.
A significant drop in clonoSEQ clinical test volumes or failure to sustain sequencing gross margins above 70%.
Inability to achieve positive consolidated Adjusted EBITDA and free cash flow by the end of fiscal year 2026.
Regulatory setbacks or unfavorable changes in Medicare/private payer reimbursement policies for MRD testing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.